Leuprorelin (Leuprolide) |
| Catalog No.GC31000 |
Leuprorelin (Leuprolide) est un analogue de l'hormone de libération de la gonadotrophine (GnRH) qui agit en tant qu'un agoniste au niveau du récepteur de GnRH de l'hypophyse.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 53714-56-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Leuprorelin (Leuprolide) est un analogue de l'hormone de libération de la gonadotrophine (GnRH) qui agit en tant qu'un agoniste au niveau du récepteur de GnRH de l'hypophyse[1]. Leuprorelin est principalement utilisé pour traiter les maladies variées liées aux hormones sexuelles, celles qui comprennent le cancer de la prostate avancé, l'endométriose et la puberté précoce. L'administration continue de Leuprorelin peut induire une désensibilisation de l'hypophyse et/ou une réduction de la régulation des récepteurs, ainsi donc, supprimer le niveau de gonadotrophines et d'hormones sexuelles dans la circulation sanguin, ce qui entraîne l'hypogonadisme[3, 4]. Leuprorelin est plus stable que GnRH naturelle et possède une affinité pour le récepteur plus forte[5].
References:
[1] Casati L, Ciceri S, Maggi R, et al. Physiological and pharmacological overview of the gonadotropin releasing hormone[J]. Biochemical pharmacology, 2023, 212: 115553.
[2] Plosker G L, Brogden R N. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders[J]. Drugs, 1994, 48(6): 930-967.
[3] Wu H M, Chang H M, Leung P C K. Gonadotropin-releasing hormone analogs: Mechanisms of action and clinical applications in female reproduction[J]. Frontiers in neuroendocrinology, 2021, 60: 100876.
[4] Wuttke W, Jarry H, Feleder C, et al. The neurochemistry of the GnRH pulse generator[J]. Acta neurobiologiae experimentalis, 1996, 56(3): 707-713.
[5] Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin[J]. Clinical pharmacokinetics, 2002, 41: 485-504.
| Cas No. | 53714-56-0 | SDF | |
| Canonical SMILES | {pGlu}-His-Trp-Ser-Tyr-{d-Leu}-Leu-Arg-Pro-NHEt | ||
| Formula | C59H84N16O12 | M.Wt | 1209.4 |
| Solubility | >20.6 mg/mL in H2O; >22 mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 826.9 μL | 4.1343 mL | 8.2686 mL |
| 5 mM | 165.4 μL | 826.9 μL | 1.6537 mL |
| 10 mM | 82.7 μL | 413.4 μL | 826.9 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 26 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *